Janux Therapeutics Statistics
Total Valuation
JANX has a market cap or net worth of $1.11 billion. The enterprise value is $160.32 million.
| Market Cap | 1.11B |
| Enterprise Value | 160.32M |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
JANX has 61.14 million shares outstanding. The number of shares has increased by 6.20% in one year.
| Current Share Class | 61.14M |
| Shares Outstanding | 61.14M |
| Shares Change (YoY) | +6.20% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 5.92% |
| Owned by Institutions (%) | 76.33% |
| Float | 42.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 47.39 |
| Forward PS | 60.99 |
| PB Ratio | 1.27 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.35, with a Debt / Equity ratio of 0.02.
| Current Ratio | 16.35 |
| Quick Ratio | 16.25 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -10.70% and return on invested capital (ROIC) is -9.15%.
| Return on Equity (ROE) | -10.70% |
| Return on Assets (ROA) | -8.80% |
| Return on Invested Capital (ROIC) | -9.15% |
| Return on Capital Employed (ROCE) | -15.15% |
| Weighted Average Cost of Capital (WACC) | 17.78% |
| Revenue Per Employee | $212,389 |
| Profits Per Employee | -$907,894 |
| Employee Count | 113 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.20% in the last 52 weeks. The beta is 2.52, so JANX's price volatility has been higher than the market average.
| Beta (5Y) | 2.52 |
| 52-Week Price Change | -22.20% |
| 50-Day Moving Average | 16.82 |
| 200-Day Moving Average | 15.44 |
| Relative Strength Index (RSI) | 54.31 |
| Average Volume (20 Days) | 832,290 |
Short Selling Information
The latest short interest is 6.63 million, so 10.84% of the outstanding shares have been sold short.
| Short Interest | 6.63M |
| Short Previous Month | 5.92M |
| Short % of Shares Out | 10.84% |
| Short % of Float | 15.58% |
| Short Ratio (days to cover) | 9.28 |
Income Statement
In the last 12 months, JANX had revenue of $24.00 million and -$102.59 million in losses. Loss per share was -$1.64.
| Revenue | 24.00M |
| Gross Profit | -99.98M |
| Operating Income | -143.56M |
| Pretax Income | -102.59M |
| Net Income | -102.59M |
| EBITDA | -141.65M |
| EBIT | -143.56M |
| Loss Per Share | -$1.64 |
Balance Sheet
The company has $970.91 million in cash and $20.99 million in debt, with a net cash position of $949.92 million or $15.54 per share.
| Cash & Cash Equivalents | 970.91M |
| Total Debt | 20.99M |
| Net Cash | 949.92M |
| Net Cash Per Share | $15.54 |
| Equity (Book Value) | 927.98M |
| Book Value Per Share | 15.19 |
| Working Capital | 923.19M |
Cash Flow
In the last 12 months, operating cash flow was -$41.25 million and capital expenditures -$674,000, giving a free cash flow of -$41.93 million.
| Operating Cash Flow | -41.25M |
| Capital Expenditures | -674,000 |
| Depreciation & Amortization | 1.90M |
| Net Borrowing | n/a |
| Free Cash Flow | -41.93M |
| FCF Per Share | -$0.69 |
Margins
| Gross Margin | n/a |
| Operating Margin | -598.15% |
| Pretax Margin | -427.47% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
JANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.20% |
| Shareholder Yield | -6.20% |
| Earnings Yield | -9.02% |
| FCF Yield | -3.69% |
Analyst Forecast
The average price target for JANX is $36.24, which is 99.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $36.24 |
| Price Target Difference | 99.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | -5.30% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
JANX has an Altman Z-Score of 8.77 and a Piotroski F-Score of 3.
| Altman Z-Score | 8.77 |
| Piotroski F-Score | 3 |